What it does · why the stock collapsed
If Realty Income is the calm, reliable landlord, Alexandria is its opposite in almost every way — and that is exactly why it's instructive to study them together. Alexandria is the pioneer and largest owner of laboratory real estate — the specialised buildings where biotech and pharma companies do their research. It doesn't just own boxes; it develops entire "megacampus" ecosystems clustered right next to the great research hubs: Cambridge (by MIT and Harvard), South San Francisco (by UCSF and Stanford), San Diego, Seattle. Its tenants are the companies trying to cure cancer.
Founded in 1994 by Joel Marcus, Alexandria more or less invented this niche and rode it to greatness — until it didn't. This is a business in distress. After a euphoric building boom, the lab market is badly oversupplied; higher interest rates and a brutal biotech funding winter have gutted tenant demand; and the stock has fallen roughly 71% from its 2021 peak of ~$183 to about $53. In 2025 it took $1.7 billion of impairments (writing down the value of its buildings) and cut its dividend by 45%. This is not a wonderful business at a fair price. It is a fallen one at a cheap price — and the whole question is which of those two facts matters more.
A stock at half its book value with the founder buying is the classic set-up for a bargain — or a value trap. The difference is whether that book value is real, or on its way down. That is the tension in every line below.
| Founded | 1994 · Pasadena, California (USA) · IPO 1997 |
| Sector / Industry | Real Estate · Life-Science / Lab REIT |
| Executive Chairman · CEO | Joel Marcus (founder) · Peter Moglia (CEO) |
| Portfolio | ~39M SF of lab/office · clusters: Boston, SF, San Diego (approx.) |
| Revenue (FY2025) | $3.0 B (first annual decline) |
| Market cap · dividend yield | ~$9.2 B (was ~$32 B in 2020) · ~5.4% |
Development risk, not net-lease calm
The REIT rules are the same as ever — Alexandria must distribute ≥90% of taxable income, grows by issuing shares and debt, and is interest-rate sensitive. (For the full REIT primer, see our Realty Income analysis.) But a life-science REIT is a very different, riskier animal than a net-lease landlord, in three ways that explain everything on this page:
So where Realty Income is a bond-like tortoise, Alexandria is a cyclical, leveraged, development-driven business tied to the boom-and-bust of biotech. It made a bold, well-timed bet for two decades — and then a badly-timed one into the 2021 peak, building into what became a glut. That is the story the numbers tell.
Why the −$8.44 EPS is fiction, and book value is the anchor
As with any REIT, ignore the earnings per share. Alexandria reported a GAAP loss of −$8.44 per share in 2025 — which looks catastrophic and is largely fiction. It reflects two huge non-cash charges: ordinary property depreciation, plus $1.7 billion of impairments (marking building values down). Add those back and you get FFO, the cash-earnings measure:
Two lenses matter for a distressed asset play like this. First, FFO: ~$9.0 per share, so the stock at $53 trades at a very low ~6× FFO — but note that FFO is now flat-to-declining (it peaked around 2024), so cheap-on-FFO only helps if the decline stops. Second — and more important here — NAV / book value: Alexandria's balance sheet carries equity of roughly $103 per share, so at $53 the stock trades at about half of book. That is the deep-value magnet. The catch: book value is management's estimate of what the buildings are worth, and the $1.4B impairment proves that number is falling. Buying at 0.5× book is only a bargain if the "1.0×" doesn't keep shrinking toward you.
A simple business, a hard-to-call cycle
What you must believe to own it is a chain of hopeful "ifs": that biotech funding recovers, that the lab oversupply clears without years of falling rents, that book value stops being written down, and that the dividend holds. Each is plausible; none is knowable. That is why this belongs in the speculative / special-situation drawer, not the "wonderful business" one.
Irreplaceable locations — in an oversupplied market
Alexandria does have a real, if cyclical, moat — and it's more interesting than a generic landlord's:
Irreplaceable cluster locations. You cannot simply build a new lab campus next to MIT or UCSF — the land is gone and the adjacency is priceless. Being at the centre of the Cambridge or South-SF innovation cluster, where the talent and the science are, is a genuine, hard-to-replicate advantage.
Purpose-built, sticky buildings. Lab space is specialised — heavy ventilation, power, vibration control, chemical handling. It's expensive to build, hard to convert, and once a biotech installs its equipment and its scientists, moving is painful. That creates real switching costs.
A 30-year ecosystem and brand. Alexandria's relationships, its venture arm, and its reputation make it the default landlord for serious life-science tenants.
But the moat is being tested. A moat protects returns; it does not make a commodity scarce when everyone overbuilds it. Right now there is too much lab space, so even irreplaceable locations are seeing softer rents and occupancy. The moat is real and will likely matter again when the cycle turns — but today it is underwater. I score it a 6: genuine, but no shield against a glut.
The three forces that broke the stock
Three things hit at once, and understanding them is understanding the whole thesis:
1. The lab-space glut. The 2020–21 life-science boom triggered a building frenzy — Alexandria among the most aggressive. By 2023–2026 the key markets (Boston, SF, San Diego) are heavily oversupplied, pushing vacancy up and rents down. Alexandria's occupancy has slipped to ~88% (early 2026, from a ~95% norm), rent spreads on renewals are turning negative, and its revenue declined in 2025 for the first time — with analysts modelling further declines toward ~$2.6B.
2. Interest rates. A REIT's oldest enemy. Higher-for-longer rates raised Alexandria's borrowing costs, made its yield less special, and — via higher cap rates — lowered what its buildings are worth (hence the $1.4B impairment).
3. The biotech funding winter. Its tenants live on venture capital and IPOs. When that funding froze, new-lab demand collapsed and some tenants failed — the demand side of Alexandria's market went cold at the worst moment.
The response — the dividend cut. In late 2025 Alexandria cut its dividend 45% (from $1.32 to $0.72 a quarter). For a company with a long dividend-growth record, this was a shock — and the honest read is mixed: it was prudent (it retains ~$400M/yr to cut debt and avoid issuing stock below book), but it was also a clear signal that management is playing defence, not confidence. Alexandria is also selling ~$2.9 billion of buildings in 2026 (after ~$1.8B in 2025) to cut debt — raising cash by shrinking, which tells you how defensive the posture has become.
The pioneer — and the buy that matters
Management's record here is genuinely double-edged, and the ownership signal is the single most interesting fact in the whole report.
Weigh both sides honestly. The bear reads: this management over-built into a bubble and just cut the dividend — why trust them now? The bull reads: the founder, who knows these assets better than anyone alive, is putting his own money in near the bottom, and the company is buying back stock at half of book. Insider buying isn't proof of anything — but a founder buying his own beaten-down stock is one of the more meaningful signals in investing, and it deserves real weight here.
A boom, a stall, and a write-down
| Metric (REIT-appropriate) | Value | Read |
|---|---|---|
| FFO / share | ~$9.0 | ◆ peaked ~2024, now declining |
| Revenue (FY2024 → FY2025) | $3.05B → $2.97B | ▼ first decline — occupancy softening |
| 2025 net result | −$1.4B | ▼ impairments (non-cash write-downs) |
| Book value / share | ~$103 | ◆ stock at ~0.5× — but book is falling |
| Occupancy | ~88% | ▼ down from ~95% — the glut |
| Dividend / share (annualised) | $5.28 → $2.88 | ▼ cut 45% in late 2025 |
| Net debt / EBITDA (normalised) | ~6x | ◆ leveraged; BBB+/Baa2, both cut/negative |
| Shares (2016 → 2025) | 76M → 170M | ◆ ~2.2× — issued to fund the build |
The arc is unmistakable. From 2016 to 2024, revenue tripled and Alexandria was a darling — a growth REIT compounding FFO per share. Then, in 2025, everything turned at once: revenue fell for the first time, FFO per share stalled, a $1.4B impairment confirmed the buildings are worth less than the books said, and the dividend was cut. The one number that flatters is the discount to book — but a book value that just took a billion-dollar haircut is a moving target. This is a company whose fundamentals are still going the wrong way; the cheapness is real, but so is the deterioration.
Cheap on assets — if the assets hold
| Yardstick | Today | Note | Read |
|---|---|---|---|
| Price / FFO | ~6x | vs ~15× a healthy REIT | very low — but FFO falling |
| Price / Book (≈ NAV) | ~0.5x | $53 vs ~$103 book | the deep-value case |
| Dividend yield (post-cut) | ~5.4% | now well-covered (~31% of FFO) | safer after the cut |
| P/E — reported earnings | n/m | GAAP loss — IGNORE (REIT) | meaningless |
| Analysts' mean target | $51 | ~4% BELOW today's price | no upside seen |
This is the crux, and it's genuinely two-sided. The bull sees a portfolio of irreplaceable lab campuses on sale at half of book and ~6× cash flow, with a 5.4% yield and the founder buying — a classic contrarian bargain. The bear sees why it's cheap: revenue, occupancy, FFO and book value are all still falling, analysts (~$51) see no upside, and the discount to book simply prices in the impairments yet to come. One number to explicitly ignore: the model-driven DCF of ~$238 is not remotely credible for a business in this state — treat it as noise. The honest verdict: the value is real only if the deterioration stops. You are buying a cheap asset with a falling knife attached.
Why the knife may keep falling
The risks here are not hypothetical — they are actively playing out. The lab glut could take years to absorb, keeping rents and occupancy under pressure; the biotech funding drought could persist, starving demand and bankrupting tenants; and each downward re-rating of property values means more impairments and a lower book value — eroding the very discount that makes the stock look cheap. Layer on real leverage (~6× net debt/EBITDA) into higher rates, and you have a business where the downside is real and the timing of any recovery is unknowable. The dividend, freshly cut, is safer now — but nothing here is guaranteed. This is the highest-risk name in this series, and it should be treated as such.
Let me be plain: this is the first business in this series I would call speculative rather than wonderful, and I want to tell you honestly why it tempts me anyway — and why I still stop short.
Alexandria is a fallen pioneer. Its founder, Joel Marcus, more or less invented the idea of building laboratory campuses next to the world's great research universities, and for thirty years it was a marvellous business — irreplaceable locations, sticky purpose-built buildings, a growing rent and a growing dividend. But great businesses can be run into cyclical walls, and this one was: management built aggressively into the 2020–21 mania, and then the tide went out on three fronts at once — a glut of lab space, a spike in interest rates, and a biotech funding winter that froze the very tenants it depends on. The result is a stock down more than three-quarters, a billion-dollar write-down of its own buildings, and — the unkindest cut — a dividend slashed nearly in half.
And yet. It now trades at roughly half of its stated book value and six times its cash flow, pays a covered 5.4% yield, and — the fact I keep returning to — the founder is buying his own stock in the open market near the lows. A man who knows these assets better than any analyst alive is voting with his own wallet that they are worth more than $53. When the person with the most information and the most to lose is buying, a prudent investor at least sits up and pays attention. This is the shape of a classic contrarian bargain: a good asset, temporarily unloved, on sale below what it would fetch in a private market.
So why do I not simply buy it? Because a discount to book value is only a bargain if the book value is real and stops falling — and here it is demonstrably still falling. Revenue is declining, occupancy is slipping, cash flow has stalled, and every quarter of the glut invites another impairment that shrinks the very "1.0×" I'd be buying at 0.5×. The analysts, tellingly, see no upside at all. I have spent a lifetime learning that a cheap, deteriorating asset is one of the most seductive traps in investing — the "value" is genuine right up until the value keeps eroding beneath you. Catching a falling knife has cost me before, and I am too old to enjoy the exercise.
What, then, would I do? I would watch it closely, with real interest, and wait for a turn. I do not buy declining fundamentals on hope, however cheap — I want to see the knife hit the floor first: occupancy stabilising, the impairments ending, the biotech funding taps reopening. If those arrive, this could prove a wonderful contrarian purchase, and the founder will have been right to buy early. For the patient value investor who genuinely understands the life-science cycle and can stomach the volatility, a starter position near the $40s — where Mr. Marcus himself was buying — is a defensible bet. But for most of us, and for me, the honest answer is: a fascinating cheap asset, not yet a safe one. Interested, respectful — and waiting.